Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Aveo will soon find out whether Fotivda has a future, while Glaxo awaits data with an even longer-lasting HIV doublet.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.